ADVISORY, Oct. 24, 2017 (GLOBE NEWSWIRE) --
Optinose (Nasdaq:OPTN), a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for directly by otolaryngology (ENT) or allergy specialists, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Larry G. Pickering, Vice Chairman of the Board of Directors, andPeter K. Miller, Chief Executive Officer, will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, October 25, 2017 – 9:15 a.m. to 9:30 a.m. ET
Optinose Media Contact:
Nasdaq MarketSite Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for directly by, or in consultation with, otolaryngology (ENT) or allergy specialists. The Company’s first two products rely on patented Exhalation Delivery Systems (EDS) capable of deep intranasal deposition of medication. These exhalation delivery systems enable creation of products with the potential for meaningful new clinical benefits. Optinose successfully developed and out-licensed its first product at the end of Phase 3 development, Onzetra® Xsail® (sumatriptan nasal powder), to Avanir Pharmaceuticals (since acquired by Otsuka Pharmaceutical Co., Ltd.) Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis. We expect subsequent Optinose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to include those using EDS and other technologies. The Company is also currently engaged in the early development of products for neurologic orphan diseases where the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (Prader-Willi Syndrome, Autism, others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway. To learn more, please visit www.optinose.com.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.